Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid.In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD.

Property Value
dbo:abstract
  • Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid.In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.On July 26, 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza. (en)
  • Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. competing against GlaxoSmithKline's Lovaza. (en)
dbo:industry
dbo:location
dbo:numberOfEmployees
  • 50 (xsd:integer)
  • 400 (xsd:integer)
dbo:thumbnail
dbo:type
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2017-09-26 13:42:29Z (xsd:date)
  • 2018-04-26 06:35:06Z (xsd:date)
  • 2019-04-18 01:05:58Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 36552790 (xsd:integer)
dbo:wikiPageLength
  • 6713 (xsd:integer)
  • 7917 (xsd:integer)
dbo:wikiPageModified
  • 2018-02-05 17:41:59Z (xsd:date)
  • 2019-04-18 00:52:23Z (xsd:date)
dbo:wikiPageOutDegree
  • 18 (xsd:integer)
dbo:wikiPageRevisionID
  • 824159286 (xsd:integer)
  • 892960497 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:foundation
  • 1993 (xsd:integer)
  • ParseResult(1993,None,None)
dbp:industry
dbp:location
  • Bedminster, New Jersey U.S. (en)
dbp:logo
  • Amarin logo.jpg (en)
dbp:name
  • Amarin Corporation (en)
dbp:numEmployees
  • 50 (xsd:integer)
  • 400 (xsd:integer)
  • ParseResult(400,None,None)
dbp:products
  • Vascepa (en)
dbp:type
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid.In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. (en)
  • Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. competing against GlaxoSmithKline's Lovaza. (en)
rdfs:label
  • Amarin Corporation (en)
owl:sameAs
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Amarin Corporation (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of